Shilpa Medicare gets USFDA EIR for Raichur API Unit
Raichur: Shilpa Medicare Limited has announced the receipt of Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at API manufacturing site located at Raichur, Karnataka, India during the period between "03rd February and 07th February 2020". USFDA has determined that the inspection classification of this facility is "NO ACTION INDICATED" ("NAI").
Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India.
The commercial production in the SML was started in November 1989.